Recurrent amplification of MYC and TNFRSF11B in 8q24 is associated with poor survival in patients with gastric cancer

Gastric Cancer

Volumn 19, Issue 1, 2016, Pages 116-127

  Wang, Xiaohong ^a   Liu, Yiqiang ^a   Shao, Duanfang ^a   Qian, Ziliang ^b   Dong, Zhengwei ^b   Sun, Yun ^b   Xing, Xiaofang ^a   Cheng, Xiaojing ^a   Du, Hong ^a   Hu, Ying ^a   Li, Yingai ^a   Li, Lin ^a   Dong, Bin ^a   Li, Ziyu ^a   Wu, Aiwen ^a   Wu, Xiaojiang ^a   Bu, Zhaode ^a   Zong, Xianglong ^a   Zhu, Guanshan ^b   Ji, Qunsheng ^b   Wen, Xian zi ^a   Zhang, Lian hai ^a   Ji, Jia fu ^a   more..

^a PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

^b ASTRAZENECA   (United Kingdom)

Author keywords

8q24; Gastric cancer; MYC; Survival; TNFRSF11B

Indexed keywords

DNA; GELATINASE B; MYC PROTEIN; PROTEIN TYROSINE KINASE; OSTEOPROTEGERIN; TNFRSF11B PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER GROWTH; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; COHORT ANALYSIS; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; COPY NUMBER VARIATION; CSE1L GENE; DISEASE ASSOCIATION; DNA MICROARRAY; ESRP1 GENE; FEMALE; GASTRECTOMY; GENE; GENE AMPLIFICATION; GENE LOCUS; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; MMP9 GENE; ONCOGENE MYC; PRIORITY JOURNAL; STOMACH CANCER; TNFRSF11B GENE; TUMOR INVASION; VALIDATION PROCESS; VERY ELDERLY; CHROMOSOME 8; GENE DOSAGE; GENETICS; MIDDLE AGED; MORTALITY; PATHOLOGY; PROCEDURES; PROGNOSIS; STOMACH TUMOR; SURVIVAL ANALYSIS;

ADULT; AGED; AGED, 80 AND OVER; CHROMOSOMES, HUMAN, PAIR 8; COHORT STUDIES; COMPARATIVE GENOMIC HYBRIDIZATION; FEMALE; GENE AMPLIFICATION; GENE DOSAGE; GENES, MYC; HUMANS; MALE; MIDDLE AGED; OSTEOPROTEGERIN; PROGNOSIS; STOMACH NEOPLASMS; SURVIVAL ANALYSIS;

EID: 84951569225     PISSN: 14363291     EISSN: 14363305     Source Type: Journal    
DOI: 10.1007/s10120-015-0467-2     Document Type: Article

References (39)

1. Chen W, Gao N, Shen Y, Cen JN. Hypermethylation downregulates Runx3 gene expression and its restoration suppresses gastric epithelial cell growth by inducing p27 and caspase3 in human gastric cancer. J Gastroenterol Hepatol. 2010;25:823–31.
2. Tada M, Kanai F, Tanaka Y, Sanada M, Nannya Y, Tateishi K, et al. Prognostic significance of genetic alterations detected by high-density single nucleotide polymorphism array in gastric cancer. Cancer Sci. 2010;101:1261–9.
3. Yoshida S, Matsumoto K, Arao T, Taniguchi H, Goto I, Hanafusa T, et al. Gene amplification of ribosomal protein S6 kinase-1 and -2 in gastric cancer. Anticancer Res. 2013;33:469–75.
4. Marenne G, Real FX, Rothman N, Rodriguez-Santiago B, Perez-Jurado L, Kogevinas M, et al. Genome-wide CNV analysis replicates the association between GSTM1 deletion and bladder cancer: a support for using continuous measurement from SNP-array data. BMC Genomics. 2012;13:326.
5. Uchida M, Tsukamoto Y, Uchida T, Ishikawa Y, Nagai T, Hijiya N, et al. Genomic profiling of gastric carcinoma in situ and adenomas by array-based comparative genomic hybridization. J Pathol. 2010;221:96–105.
6. Peng DF, Sugihara H, Mukaisho K, Tsubosa Y, Hattori T. Alterations of chromosomal copy number during progression of diffuse-type gastric carcinomas: metaphase- and array-based comparative genomic hybridization analyses of multiple samples from individual tumours. J Pathol. 2003;201:439–50.
7. Morohara K, Nakao K, Tajima Y, Nishino N, Yamazaki K, Kaetsu T, et al. Analysis by comparative genomic hybridization of gastric cancer with peritoneal dissemination and/or positive peritoneal cytology. Cancer Genet Cytogenet. 2005;161:57–62.
8. Leung SY, Ho C, Tu IP, Li R, So S, Chu KM, et al. Comprehensive analysis of 19q12 amplicon in human gastric cancers. Mod Pathol. 2006;19:854–63.
9. Kang JU, Kang JJ, Kwon KC, Park JW, Jeong TE, Noh SM, et al. Genetic alterations in primary gastric carcinomas correlated with clinicopathological variables by array comparative genomic hybridization. J Korean Med Sci. 2006;21:656–65.
10. Tsukamoto Y, Uchida T, Karnan S, Noguchi T, Nguyen LT, Tanigawa M, et al. Genome-wide analysis of DNA copy number alterations and gene expression in gastric cancer. J Pathol. 2008;216:471–82.
11. Takada H, Imoto I, Tsuda H, Sonoda I, Ichikura T, Mochizuki H, et al. Screening of DNA copy-number aberrations in gastric cancer cell lines by array-based comparative genomic hybridization. Cancer Sci. 2005;96:100–10.
12. Weiss MM, Kuipers EJ, Postma C, Snijders AM, Pinkel D, Meuwissen SG, et al. Genomic alterations in primary gastric adenocarcinomas correlate with clinicopathological characteristics and survival. Cell Oncol. 2004;26:307–17.
13. Jun KH, Kim SY, Yoon JH, Song JH, Park WS. Amplification of the UQCRFS1 gene in gastric cancers. J Gastric Cancer. 2012;12:73–80.
14. Park CH, Rha SY, Jeung HC, Kang SH, Ki DH, Lee WS, et al. Identification of novel gastric cancer-associated CNVs by integrated analysis of microarray. J Surg Oncol. 2010;102:454–61.
15. Varis A, van Rees B, Weterman M, Ristimaki A, Offerhaus J, Knuutila S. DNA copy number changes in young gastric cancer patients with special reference to chromosome 19. Br J Cancer. 2003;88:1914–9.
16. Stocks SC, Pratt N, Sales M, Johnston DA, Thompson AM, Carey FA, et al. Chromosomal imbalances in gastric and esophageal adenocarcinoma: specific comparative genomic hybridization-detected abnormalities segregate with junctional adenocarcinomas. Genes Chromosomes Cancer. 2001;32:50–8.
17. Gumus-Akay G, Unal AE, Elhan AH, Bayar S, Karadayt K, Sunguroglu A, et al. DNA copy number changes in gastric adenocarcinomas: high resolution-comparative genomic hybridization study in Turkey. Arch Med Res. 2009;40:551–60.
18. Canales RD, Luo Y, Willey JC, Austermiller B, Barbacioru CC, Boysen C, et al. Evaluation of DNA microarray results with quantitative gene expression platforms. Nat Biotechnol. 2006;24:1115–22.
19. Huang LYD, Wu C, Zhai K, Jiang G, Cao G, Wang C, Liu Y, Sun M, Li Z, Tan W, Lin D. Copy number variation at 6q13 functions as a long-range regulator and is associated with pancreatic cancer risk. Carcinogenesis. 2011;33:94–100.
20. van Heumen BW, Roelofs HM, te Morsche RH, Nagengast FM, Peters WH. Duodenal mucosal risk markers in patients with familial adenomatous polyposis: effects of celecoxib/ursodeoxycholic acid co-treatment and comparison with patient controls. Orphanet J Rare Dis. 2013;8:181.
21. Ajani JA, Bentrem DJ, Besh S, D’Amico TA, Das P, Denlinger C, et al. Gastric cancer, version 2.2013: featured updates to the NCCN guidelines. J Natl Compr Cancer Netw. 2013;11:531–46.
22. Yu S, Bittel DC, Kibiryeva N, Zwick DL, Cooley LD. Validation of the Agilent 244 K oligonucleotide array-based comparative genomic hybridization platform for clinical cytogenetic diagnosis. Am J Clin Pathol. 2009;132:349–60.
23. El Gammal AT, Bruchmann M, Zustin J, Isbarn H, Hellwinkel OJ, Kollermann J, et al. Chromosome 8p deletions and 8q gains are associated with tumor progression and poor prognosis in prostate cancer. Clin Cancer Res. 2010;16:56–64.
24. Ribeiro FR, Jeronimo C, Henrique R, Fonseca D, Oliveira J, Lothe RA, et al. 8q gain is an independent predictor of poor survival in diagnostic needle biopsies from prostate cancer suspects. Clin Cancer Res. 2006;12:3961–70.
25. Klatte T, Kroeger N, Rampersaud EN, Birkhauser FD, Logan JE, Sonn G, et al. Gain of chromosome 8q is associated with metastases and poor survival of patients with clear cell renal cell carcinoma. Cancer. 2012;118:5777–82.
26. Roessler S, Long EL, Budhu A, Chen Y, Zhao X, Ji J, et al. Integrative genomic identification of genes on 8p associated with hepatocellular carcinoma progression and patient survival. Gastroenterology. 2012;142:957–66.e12.
27. Helms MW, Kemming D, Pospisil H, Vogt U, Buerger H, Korsching E, et al. Squalene epoxidase, located on chromosome 8q24.1, is upregulated in 8q+ breast cancer and indicates poor clinical outcome in stage I and II disease. Br J Cancer. 2008;99:774–80.
28. Kratz JR, He J, Van Den Eeden SK, Zhu ZH, Gao W, Pham PT, et al. A practical molecular assay to predict survival in resected non-squamous, non-small-cell lung cancer: development and international validation studies. Lancet. 2012;379:823–32.
29. Leal MF, Calcagno DQ, de Fátima Ferreira Borges da Costa J, Silva TC, Khayat AS, Chen ES, et al. MYC, TP53, and chromosome 17 copy-number alterations in multiple gastric cancer cell lines and in their parental primary tumors. J Biomed Biotechnol. 2011;2011:631268.
30. Calcagno DQ, Freitas VM, Leal MF, de Souza CR, Demachki S, Montenegro R, et al. MYC, FBXW7 and TP53 copy number variation and expression in gastric cancer. BMC Gastroenterol. 2013;13:141.
31. de Souza CR, Leal MF, Calcagno DQ, Costa Sozinho EK, Borges Bdo N, Montenegro RC, et al. MYC deregulation in gastric cancer and its clinicopathological implications. PLoS One. 2013;8:e64420.
32. Zhang L, Hou Y, Ashktorab H, Gao L, Xu Y, Wu K, et al. The impact of C-MYC gene expression on gastric cancer cell. Mol Cell Biochem. 2010;344:125–35.
33. Holen I, Cross SS, Neville-Webbe HL, Cross NA, Balasubramanian SP, Croucher PI, et al. Osteoprotegerin (OPG) expression by breast cancer cells in vitro and breast tumours in vivo—a role in tumour cell survival? Breast Cancer Res Treat. 2005;92:207–15.
34. Holen I, Shipman CM. Role of osteoprotegerin (OPG) in cancer. Clin Sci (Lond). 2006;110:279–91.
35. Chen G, Sircar K, Aprikian A, Potti A, Goltzman D, Rabbani SA. Expression of RANKL/RANK/OPG in primary and metastatic human prostate cancer as markers of disease stage and functional regulation. Cancer. 2006;107:289–98.
36. Ito R, Nakayama H, Yoshida K, Kuraoka K, Motoshita J, Oda N, et al. Expression of osteoprotegerin correlates with aggressiveness and poor prognosis of gastric carcinoma. Virchows Arch. 2003;443:146–51.
37. Neville-Webbe HL, Cross NA, Eaton CL, Nyambo R, Evans CA, Coleman RE, et al. Osteoprotegerin (OPG) produced by bone marrow stromal cells protects breast cancer cells from TRAIL-induced apoptosis. Breast Cancer Res Treat. 2004;86:269–79.
38. Lane D, Matte I, Rancourt C, Piche A. Osteoprotegerin (OPG) protects ovarian cancer cells from TRAIL-induced apoptosis but does not contribute to malignant ascites-mediated attenuation of TRAIL-induced apoptosis. J Ovarian Res. 2012;5:34.
39. De Toni EN, Thieme SE, Herbst A, Behrens A, Stieber P, Jung A, et al. OPG is regulated by β-catenin and mediates resistance to TRAIL-induced apoptosis in colon cancer. Clin Cancer Res. 2008;14:4713–8.